Bleeding related to etonogestrel subdermal implant in a US population

Contraception

Volumn 83, Issue 5, 2011, Pages 426-430

  Casey, Petra M ^a   Long, Margaret E ^a   Marnach, Mary L ^a   Bury, Jessica E ^b,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c Santa Clara Valley Hospital   (United States)

Author keywords

Contraceptive implant; Etonogestrel subdermal implant; Menstrual bleeding; Vaginal bleeding

Indexed keywords

ETONOGESTREL;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; BODY MASS; CONSULTATION; CONTRACEPTION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE PERSONNEL; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENSTRUATION DISORDER; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DEVICE REMOVAL; DRUG IMPLANTS; FEMALE; HUMANS; METRORRHAGIA; MINNESOTA; PREGNANCY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79954415235     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.09.012     Document Type: Article

References (25)

1. Lipetz C, Phillips C, Fleming C. Actual cost of providing long-acting reversible contraception: a study of Implanon cost. J Fam Plann Reprod Health Care 2009;35:75-9.
2. Lipetz C, Phillips CJ, Fleming CF. The cost-effectiveness of a longacting reversible contraceptive (Implanon) relative to oral contraception in a community setting. Contraception 2009;79:304-9.
3. Mavranezouli I. The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008;23:1338-45. (Pubitemid 351770574)
4. Weisberg E, Fraser I. Australian women's experience with Implanon. Aust Fam Physician 2005;34:694-6.
5. Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852-61.
6. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999;14:976-81. (Pubitemid 29176477)
7. Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998;3:85-91. (Pubitemid 128690533)
8. Thamkhantho M, Jivasak-Apimas S, Angsuwathana S, et al. Oneyear assessment of women receiving sub-dermal contraceptive implant at Siriraj Family Planning Clinic. J Med Assoc Thai 2008; 91:775-80.
9. Agrawal A, Robinson C. An assessment of the first 3 years' use of Implanon in Luton. J Fam Plann Reprod Health Care 2005;31:310-2.
10. Funk S, Miller MM, Mishell Jr DR, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319-26. (Pubitemid 40602307)
11. Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13(Supp 1):13-28. (Pubitemid 351364453)
12. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-53.
13. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527-32.
14. Riney S, O'Shea B, Forde A. Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting. Ir Med J 2009;102:24-5.
15. Yildizbas B, Sahin HG, Kolusari A, et al. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care 2007;12:248-52. (Pubitemid 47347168)
16. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006;74:287-9. (Pubitemid 44373888)
17. Flores JB, Balderas ML, Bonilla MC, et al. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet 2005;90:228-33. (Pubitemid 41138922)
18. Smith A, Reuter S. An assessment of the use of Implanon in three community services. J Fam Plann Reprod Health Care 2002;28:193-6. (Pubitemid 35439631)
19. Zheng SR, Zheng HM, Qian SZ, et al. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracept Reprod Health Care 1999;4:85-93.
20. Shering-Plough, NV Organon. Implanon (etonogestrel implant) [package insert]. [Internet] [cited 2009 Nov 8]. Available from http://www.spfiles.com/ piimplanon.pd.pdf.
21. Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70:47-54. (Pubitemid 38781978)
22. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5 (Supp 2):21-8. (Pubitemid 32171234)
23. Hidalgo MM, Lisondo C, Juliato CT, et al. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception 2006;73:532-6.
24. Lei ZW, Wu SC, Garceau RJ, et al. Effect of pretreatment counseling on discontinuation rate in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 1996;53:357.
25. Canto De Cetina TE, Canto P, et al. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 2001;63:143.